Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa pediatric study of luspatercept in beta-thalassemia
CTR20243218Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Feb 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept in beta thalassemia, hemoglobin E beta thalassemia (HbE/β-thal), sponsored by Celgene Corporation. Started Feb 2025; status: active.
02
Drugs
luspatercept
03
Conditions
beta thalassemiahemoglobin E beta thalassemia (HbE/β-thal)
Beyond the preview
Go deeper on CTR20243218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243218.